FindTrial
Sign In

Prospective Study of Percutaneous Transhepatic Papillary Balloon Dilation versus Endoscopic Retrograde Cholangio-Pancreatography for Common Bile Duct Stones in Multicenter of China

Prospective Study of Percutaneous Transhepatic Papillary Balloon Dilation versus Endoscopic Retrograde Cholangio-Pancreatography for Common Bile Duct Stones in Multicenter of China

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900028004
Enrollment
Unknown
Registered
2019-12-08
Start date
2016-07-01
Completion date
Unknown
Last updated
2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

choledocholithiasis

Interventions

Group 1:Percutaneous Transhepatic Papillary Balloon Dilation
Group 2:ERCP

Sponsors

The Second Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
19 Years to 103 Years

Inclusion criteria

Inclusion criteria: 1. common bile duct stones demonstrated by imaging modalities and serum examinations; 2. Karnofsky score >70 or ECOG score 0-2, expected life span >12 months; 3. willing to complete this clinical research and signed informed consent; 4. without severe comorbidities, including respiratory failure, heart failure or psychiatric disorders; 5. to be able to complete follow-up.

Exclusion criteria

Exclusion criteria: 1. unwilling to signed informed consent or comply with research plan; 2. with simultaneous gallbladder stones or hepatolithiasis; 3. expected life span 18s.

Design outcomes

Primary

MeasureTime frame
Technical success rate;recurrence rate;incidence of complications;exposure dose;patient compliance;—

Secondary

MeasureTime frame
hospital stay;treatment related expense;complication related expense;—

Countries

China

Contacts

Public ContactYuliang Li

The Second Hospital of Shandong University

lyl.pro@sdu.edu.cn+86 13573780666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026